Literature DB >> 19527984

Coronary stenting in warfarin treated patients.

Doron Zahger1, Reuben Ilia.   

Abstract

Dual antiplatelet therapy is standard treatment following coronary stent implantation. An important minority of patients also require chronic anticoagulation, most commonly for atrial fibrillation. There are no prospective trials to guide the selection of therapy in this situation. In this paper we review the available data and present practice recommendations. It appears that in patients who are not at high risk of bleeding, and in whom both coronary stenting and anticoagulation are considered necessary after careful consideration, drug eluting stents should be avoided as much as possible. Triple therapy with aspirin, clopidogrel and warfarin for one month, followed by the combination of aspirin and warfarin for life is the most reasonable approach.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19527984     DOI: 10.4244/eijv5i2a43

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  3 in total

1.  Follow-up and management of valvular heart disease patients with prosthetic valve: a clinical practice guideline for Indian scenario.

Authors:  Devendra Saksena; Yugal K Mishra; S Muralidharan; Vivek Kanhere; Pankaj Srivastava; C P Srivastava
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2019-01-28

2.  Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.

Authors:  Soon Yong Suh; Woong Chol Kang; Pyung Chun Oh; Hanul Choi; Chan Il Moon; Kyounghoon Lee; Seung Hwan Han; Taehoon Ahn; In Suck Choi; Eak Kyun Shin
Journal:  Heart Vessels       Date:  2013-08-24       Impact factor: 2.037

3.  Vasodilator-stimulated phosphoprotein-guided Clopidogrel maintenance therapy reduces cardiovascular events in atrial fibrillation patients requiring anticoagulation therapy and scheduled for percutaneous coronary intervention: a prospective cohort study.

Authors:  Chaoyue Hu; Xumin Zhang; Yonghua Liu; Yang Gao; Xiaohong Zhao; Hua Zhou; Yu Luo; Yaling Liu; Xiaodong Wang
Journal:  BMC Cardiovasc Disord       Date:  2018-06-18       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.